These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 1458463)
41. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224 [TBL] [Abstract][Full Text] [Related]
42. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770 [TBL] [Abstract][Full Text] [Related]
43. In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen. Simard P; Leroux JC Mol Pharm; 2010 Aug; 7(4):1098-107. PubMed ID: 20476756 [TBL] [Abstract][Full Text] [Related]
44. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797 [TBL] [Abstract][Full Text] [Related]
45. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319 [TBL] [Abstract][Full Text] [Related]
46. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Hoyer JD; Grogg KL; Hanson CA; Gamez JD; Dogan A Am J Clin Pathol; 2008 Feb; 129(2):316-23. PubMed ID: 18208813 [TBL] [Abstract][Full Text] [Related]
47. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Woodhouse CS; Morgan AC Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860 [TBL] [Abstract][Full Text] [Related]
49. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies. Christiaansen JE; Sears DW Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288 [TBL] [Abstract][Full Text] [Related]
50. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. van der Jagt RH; Badger CC; Appelbaum FR; Press OW; Matthews DC; Eary JF; Krohn KA; Bernstein ID Cancer Res; 1992 Jan; 52(1):89-94. PubMed ID: 1530769 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Balaian L; Ball ED Leuk Res; 2004 Aug; 28(8):821-9. PubMed ID: 15203280 [TBL] [Abstract][Full Text] [Related]
52. [Construction, expression and functional characterization of single chain variable fragments (scFv) against human CD33 antigen]. Chen XJ; Wang Y; Qu H; Ge XS; Zuo YF; Liao XL Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1147-9. PubMed ID: 18062889 [TBL] [Abstract][Full Text] [Related]
53. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095 [TBL] [Abstract][Full Text] [Related]
54. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980 [TBL] [Abstract][Full Text] [Related]
56. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Vitale C; Romagnani C; Falco M; Ponte M; Vitale M; Moretta A; Bacigalupo A; Moretta L; Mingari MC Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15091-6. PubMed ID: 10611343 [TBL] [Abstract][Full Text] [Related]
57. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Robillard N; Wuillème S; Lodé L; Magrangeas F; Minvielle S; Avet-Loiseau H Leukemia; 2005 Nov; 19(11):2021-2. PubMed ID: 16167057 [No Abstract] [Full Text] [Related]
59. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. Sgouros G; Graham MC; Divgi CR; Larson SM; Scheinberg DA J Nucl Med; 1993 Mar; 34(3):422-30. PubMed ID: 8441034 [TBL] [Abstract][Full Text] [Related]
60. [Preparation of monoclonal antibody against human CD33 by immunizing mice with recombinant vector]. Wang H; Liu H; Wang A; Zhen J; Wu X; Chen M; Gong M; Qu H; Zhou S; Tao X; Liao X Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Feb; 36(2):169-174. PubMed ID: 32314715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]